InfuSystem Holdings, Inc. (NYSE:INFU) Shares Bought by Barclays PLC

Barclays PLC lifted its stake in shares of InfuSystem Holdings, Inc. (NYSE:INFU) by 300.5% in the third quarter, according to the company in its most recent disclosure with the SEC. The institutional investor owned 28,597 shares of the company’s stock after buying an additional 21,457 shares during the quarter. Barclays PLC owned approximately 0.13% of InfuSystem worth $192,000 at the end of the most recent reporting period.

A number of other large investors have also recently made changes to their positions in the company. BNP Paribas Financial Markets raised its position in shares of InfuSystem by 66.4% during the 3rd quarter. BNP Paribas Financial Markets now owns 4,076 shares of the company’s stock worth $27,000 after acquiring an additional 1,626 shares in the last quarter. Rhumbline Advisers raised its holdings in InfuSystem by 13.8% during the second quarter. Rhumbline Advisers now owns 17,658 shares of the company’s stock worth $121,000 after purchasing an additional 2,145 shares in the last quarter. State Street Corp lifted its position in shares of InfuSystem by 1.1% during the 3rd quarter. State Street Corp now owns 267,012 shares of the company’s stock worth $1,789,000 after buying an additional 3,019 shares during the last quarter. Bank of New York Mellon Corp boosted its holdings in shares of InfuSystem by 6.1% in the 2nd quarter. Bank of New York Mellon Corp now owns 93,899 shares of the company’s stock valued at $641,000 after buying an additional 5,391 shares in the last quarter. Finally, Oppenheimer Asset Management Inc. grew its position in shares of InfuSystem by 28.0% in the 3rd quarter. Oppenheimer Asset Management Inc. now owns 33,337 shares of the company’s stock valued at $223,000 after buying an additional 7,295 shares during the last quarter. 71.13% of the stock is currently owned by hedge funds and other institutional investors.

Wall Street Analysts Forecast Growth

A number of brokerages recently weighed in on INFU. B. Riley initiated coverage on shares of InfuSystem in a research report on Thursday, September 26th. They issued a “buy” rating and a $13.00 price target for the company. StockNews.com raised InfuSystem from a “buy” rating to a “strong-buy” rating in a report on Friday, November 8th.

InfuSystem Price Performance

INFU stock opened at $8.32 on Tuesday. The stock has a market cap of $176.92 million, a P/E ratio of 138.69 and a beta of 1.53. The firm has a fifty day simple moving average of $8.36. The company has a debt-to-equity ratio of 0.50, a quick ratio of 1.59 and a current ratio of 1.98. InfuSystem Holdings, Inc. has a 12 month low of $5.74 and a 12 month high of $10.15.

Insider Activity

In other InfuSystem news, CEO Richard Dilorio sold 20,000 shares of the business’s stock in a transaction on Monday, November 25th. The shares were sold at an average price of $9.32, for a total value of $186,400.00. Following the transaction, the chief executive officer now directly owns 436,659 shares of the company’s stock, valued at approximately $4,069,661.88. The trade was a 4.38 % decrease in their position. The sale was disclosed in a filing with the SEC, which can be accessed through the SEC website. Corporate insiders own 10.20% of the company’s stock.

About InfuSystem

InfuSystem Holdings, Inc, through its subsidiaries, provides infusion pumps, and related products and services in the United States and Canada. The company operates in two segments, Patient Services and Device Solutions. It supplies electronic ambulatory infusion pumps and associated disposable supply kits to oncology, infusion, and hospital outpatient chemotherapy clinics for the treatment of various cancers, including colorectal cancer, pain management, and other disease states.